Leadership transition interview: Otto Buttula reflects on his tenure overseeing ColoSTAT® development and platform expansion, while incoming Chair Gavin Fox-Smith discusses advancing our cancer detection technologies. Watch the full Stockhead interview tinyurl.com/3df666kj

BreastScreen Australia's 2024 position statement recommends women be informed of their breast density. For women with dense tissue, a validated risk model like geneType™ that combines breast density + family history + polygenic risk is crucial tinyurl.com/4muvvttp

New study shows patients don't experience significant anxiety or distress when receiving personalised #breastcancer risk assessments using polygenic risk scores. Higher satisfaction with risk information linked to lower decisional regret one year later: tinyurl.com/45zu6uvs

Aus has one of the world's highest #breastcancer rates. geneType™'s risk assessment combines genetic factors with family history and breast density for personalised screening decisions. Lifetime and 10-year risk scores help inform surveillance discussions tinyurl.com/49tsewcp

🚀Big step forward for Rhythm Biosciences! We’ve entered a strategic pilot for geneType™ risk assessment platform with a major pathology partner in Australia. Helping more people understand their risk of cancer. 👉 Learn more: tinyurl.com/4ny395xa #genetype #RiskAssessment

New geneType™ trials with MSKCC (NYC) to advance PRS in breast & prostate cancer. #CancerResearch #PRS #BRCA #BreastCancer #ProstateCancer #Genomics #PrecisionMedicine #MSKCC #geneType #RhythmBiosciences

As featured in The Daily Telegraph: 75% of Aussies would consider a PRS test. geneType™ helps assess risk for cancer, heart disease & more—from a simple saliva swab. Healthcare providers: learn how to offer it 👉 genetype.com #PRS #geneType tinyurl.com/4uc7bpya

We're excited to launch our Shareholder Benefits Program, starting with access to our geneType™ Cancer panels. Future plans include ColoSTAT®, our blood-based CRC test (pending approvals). 🔗 rhythmbio.com #healthtech #genomics #RHY #geneType

Rhythm Biosciences released its Q4 FY25 4C & business update. Highlights include ColoSTAT® in final validation, geneType™ partnership signed, NATA accreditation reinstated, $1M non-dilutive funding secured. Great start for FY26. 📄 Read more: tinyurl.com/4ny395xa #ASX #RHY

🚨 ColoSTAT® milestoone shows consistent performance across all colorectal cancer stages (I–IV) in 300 patient samples. A key step toward commercialisation and improving early cancer detection. #ColoSTAT #ColorectalCancer #CancerDiagnostics #EarlyDetection #RhythmBiosciences

#Prostatecancer affects 1 in 6 Australian men. geneType™'s risk assessment combines genetic factors with clinical history to inform personalised PSA screening decisions. Helping healthcare providers discuss individualised approaches with male patients tinyurl.com/2crrzfap

Runner of the Week from Bulls N' Bears highlights ColoSTAT® progress. Clinical study of 300 patients showed consistent colorectal #cancer detection across all stages. "This biotech minnow could help rewrite the script on cancer screening." Read: tinyurl.com/3xbk66sk $RHY

NEWS: $3.75M raise at $0.09 per share to advance ColoSTAT® launch and geneType™ commercialisation. Strong investor demand with Directors contributing $0.3m showing continued confidence. "It's a huge privilege to help in the battle against cancer" - CEO Dr David Atkins $RHY

Long Shortz with Rhythm Biosciences : $3.75M placement to accelerate cancer and genetic diagnostics buff.ly/3UXoOrd hashtag#ASX hashtag#Health $RHY

ColoSTAT® milestone - final validation complete and NATA application submitted. Over 300 clinical samples tested with strong performance results. In House Lab process validated. Manufacturing-grade kits validated. Read: rhythmbio.com $RHY

Rhythm Biosciences completes final validation of ColoSTAT colon cancer test buff.ly/TxsmlcF #ASX #Biotech $RHY Rhythm Biosciences

Rhythm enters co-marketing agreement with Know Your Lemons 🍋🍋 to promote geneType™ breast cancer risk assessment. Reaching hundreds of thousands of women through its mobile app and employee programs in the US. Perfect timing for #BreastCancerAwarenessMonth $RHY

Long Shortz with Rhythm Biosciences : Non-invasive bowel cancer test delivers strong results buff.ly/bZBQVuj #ASX #Health $RHY

Annual Report: Strong 20-month progress across our cancer diagnostics platform. ColoSTAT® restructured with strong clinical performance, geneType™ acquisition delivering first revenues, strategic partnerships re-established. Read: rhythmbio.com $RHY

This #WomensHealthWeek, consider how proactive health management includes understanding your genetic risk profile. geneType™ offers comprehensive risk assessment for breast #cancer, ovarian cancer, cardiovascular disease, diabetes and melanoma: genetype.com